Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company) reported strong fiscal 2021 results, with Q4 revenues reaching $5.135 billion, a 7.3% increase year-over-year. Diluted EPS was $0.84, up 133.3%. The company achieved revenue growth across segments, led by BD Medical's 9.2% rise. Despite a decline in COVID-19 diagnostic revenue, BD's outlook for fiscal 2022 anticipates revenue between $19.3 billion and $19.5 billion and adjusted EPS of $12.30 to $12.50, reflecting 5-6% growth. BD also increased its dividend by 4.8% and repurchased 3 million shares for $750 million.
The Board of Directors of BD (Becton, Dickinson and Company) declared a quarterly dividend of $0.87 per share, up 4.8% from the previous quarter, payable on December 31, 2021. This marks the 50th consecutive year of dividend increases, reinforcing BD's status in the S&P 500 Dividend Aristocrats Index. Additionally, the board authorized a share repurchase of up to 10 million shares, adding to the remaining 750,000 shares from a previous program. This strategic move is aimed at enhancing shareholder value, aligned with the company's 2025 strategy.
BD (Becton, Dickinson and Company) has announced a strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop a suite of COVID-19 combination diagnostic tests. This collaboration will receive initial funding of $24.7 million, potentially extending to $40.3 million. The new tests aim to simultaneously detect multiple respiratory pathogens, enhancing patient management and healthcare resource allocation. BD plans to achieve full FDA clearance for these tests, ensuring their availability even post-COVID-19 emergency.
BD (Becton, Dickinson and Company) will hold a virtual investor day on November 12, 2021, starting at 8 a.m. The event, lasting approximately four hours, will feature presentations from CEO Tom Polen and the executive leadership team, followed by Q&A sessions. A replay and additional materials will be available on BD's investor page after the event. BD is a global leader in medical technology, committed to enhancing healthcare through innovative solutions. For more information, visit bd.com.
BD (Becton, Dickinson and Company) has announced the shipment of its first over-the-counter (OTC) COVID-19 rapid antigen test, utilizing smartphone computer vision technology for result interpretation. Available for $39.99 with promotional pricing at $26.50 on Amazon, the BD Veritor™ test offers digital results in 15 minutes, simplifying at-home testing. It features automated reporting to health agencies and is suitable for individuals aged 14 and older. Authorized under Emergency Use Authorization, the test addresses common at-home testing challenges, including result interpretation and reporting.
BD (Becton, Dickinson and Company) announced the appointment of Dr. Carrie L. Byington to its board of directors, increasing the board to 13 members. Byington is the executive vice president and head of University of California Health, leading a $20 billion academic health system. Her experience includes significant roles at Texas A&M University and the University of Utah. The company views her appointment as timely, aligning with its BD 2025 strategy aimed at innovating in connected care and improving chronic disease outcomes.
On October 18, 2021, BD (Becton, Dickinson and Company) announced its new ESG strategy, Together We Advance, aimed at enhancing its commitment to health, community, and environmental stewardship. This strategy focuses on four pillars: Company Health, Planet Health, Community Health, and Human Health. BD set ambitious 2030 goals, including a 46% reduction in Scope 1 and 2 greenhouse gas emissions and carbon neutrality in direct operations by 2040. The strategy emphasizes climate change, responsible supply chains, and transparency, while aligning with the UN Sustainable Development Goals.
BD (Becton, Dickinson and Company) announced enhanced manufacturing capacity for injection devices to support U.S. vaccination efforts. Completed with the Department of Health and Human Services (HHS), the new lines bolster domestic supply amid ongoing COVID-19 challenges. This follows a $42 million investment from HHS in a previous capital project aimed at expanding BD's operations in Nebraska, underscoring a commitment to both current and future pandemic needs. BD has supplied hundreds of millions of devices, ensuring continuity in healthcare delivery as the flu season approaches.
BD (Becton, Dickinson and Company) has received 510(k) clearance from the FDA for the Rotarex™ Atherectomy System, expanding its indications to include treatment in peripheral arteries with stents, stent grafts, and bypasses. This device can now assist in the treatment of in-stent restenosis, a complication often arising in patients with peripheral arterial disease (PAD). With over a decade of clinical use, the Rotarex™ System is recognized for its efficacy in effectively managing arterial lesions and improving patient outcomes.
BD (Becton, Dickinson and Company) will report its fiscal 2021 fourth quarter and full year financial results on Nov. 4, 2021. A press release will be issued at approximately 6 a.m. ET, followed by a conference call and webcast at 8 a.m. ET to discuss the results and company strategy. Investors can access the webcast on BD's investor relations website. BD is a leading global medical technology company committed to improving healthcare through innovative technologies.